AI-Powered Pathogen Detection App: Provisional Patent Filed by FendX CEO
FendX Technologies (OTCQB: FDXTF) announced that CEO Dr. Carolyn Myers has filed a provisional patent application for an AI-powered pathogen detection platform. The patent, titled "AI Adaptive App Pathogen Detection Platform," was filed on June 25, 2025, with the United States Patent and Trademark Office.
The technology combines mobile-based imaging, biosensor technology, and artificial intelligence to enable real-time pathogen detection on surfaces using smartphones. The innovation aims to create a portable diagnostic tool for both consumer and professional applications, moving beyond traditional lab-based testing methods.
FendX Technologies (OTCQB: FDXTF) ha comunicato che l’amministratore delegato, la Dr.ssa Carolyn Myers, ha depositato una domanda di brevetto provvisoria per una piattaforma di rilevamento patogeni basata sull’IA. Il brevetto, intitolato "AI Adaptive App Pathogen Detection Platform", è stato presentato il 25 giugno 2025 presso l’Ufficio brevetti e marchi degli Stati Uniti.
La tecnologia integra acquisizione immagini su dispositivi mobili, biosensori e intelligenza artificiale per permettere il rilevamento in tempo reale di patogeni su superfici tramite smartphone. L’innovazione punta a offrire uno strumento diagnostico portatile per usi sia consumer sia professionali, superando i metodi tradizionali di analisi in laboratorio.
FendX Technologies (OTCQB: FDXTF) anunció que la directora ejecutiva, la Dra. Carolyn Myers, presentó una solicitud provisional de patente para una plataforma de detección de patógenos impulsada por IA. La patente, titulada "AI Adaptive App Pathogen Detection Platform", fue presentada el 25 de junio de 2025 ante la Oficina de Patentes y Marcas de Estados Unidos.
La tecnología combina captura de imágenes en móviles, tecnología de biosensores e inteligencia artificial para permitir la detección en tiempo real de patógenos en superficies mediante smartphones. La innovación busca crear una herramienta diagnóstica portátil para aplicaciones tanto de consumo como profesionales, y avanzar más allá de los métodos tradicionales de laboratorio.
FendX Technologies (OTCQB: FDXTF)는 최고경영자(CEO)인 캐롤린 마이어스 박사가 AI 기반 병원체 검출 플랫폼에 대한 임시 특허 출원을 했다고 발표했습니다. "AI Adaptive App Pathogen Detection Platform"이라는 제목의 특허는 2025년 6월 25일 미국 특허청(USPTO)에 제출되었습니다.
이 기술은 모바일 기반 이미지 촬영, 바이오센서 기술, 인공지능을 결합해 스마트폰으로 표면상의 병원체를 실시간으로 검출할 수 있게 합니다. 이 혁신은 실험실 중심의 전통적 검사 방식을 넘어 소비자 및 전문 분야 모두에서 사용할 수 있는 휴대용 진단 도구를 목표로 합니다.
FendX Technologies (OTCQB: FDXTF) a annoncé que sa PDG, le Dr Carolyn Myers, a déposé une demande de brevet provisoire pour une plateforme de détection de pathogènes alimentée par l’IA. Le brevet, intitulé « AI Adaptive App Pathogen Detection Platform », a été déposé le 25 juin 2025 auprès de l’Office américain des brevets et des marques.
La technologie combine imagerie mobile, technologie de biocapteurs et intelligence artificielle pour permettre la détection en temps réel de pathogènes sur des surfaces via un smartphone. L’innovation vise à proposer un outil de diagnostic portable pour des usages grand public et professionnels, dépassant les méthodes d’analyse traditionnelles en laboratoire.
FendX Technologies (OTCQB: FDXTF) gab bekannt, dass CEO Dr. Carolyn Myers eine vorläufige Patentanmeldung für eine KI-gestützte Pathogenerkennungsplattform eingereicht hat. Das Patent mit dem Titel "AI Adaptive App Pathogen Detection Platform" wurde am 25. Juni 2025 beim US-Patent- und Markenamt eingereicht.
Die Technologie vereint mobilbasierte Bildgebung, Biosensor-Technologie und künstliche Intelligenz, um die Echtzeitdetektion von Krankheitserregern auf Oberflächen mittels Smartphones zu ermöglichen. Ziel der Innovation ist ein tragbares Diagnosetool für Verbraucher- und professionelle Anwendungen, das über traditionelle Laborverfahren hinausgeht.
- None.
- Patent is only in provisional stage with no guarantee of final approval
- No timeline provided for commercial development or launch
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce that its CEO, Dr. Carolyn Myers, has filed a provisional patent application with the United States Patent and Trademark Office. The application, titled "AI Adaptive App Pathogen Detection Platform" dated June 25, 2025, will be assigned to FendX as part of its expanding portfolio of hygiene-related technologies.
The invention described in the patent application is being designed to combine mobile-based imaging, biosensor technology, and artificial intelligence ("AI") to enable real-time detection of pathogens on surfaces using a mobile device such as a smartphone. The aim is to develop a portable, intelligent and user-friendly diagnostic tool for both consumer and professional use.
"Traditional diagnostic methods are powerful but often take time to detect and identify pathogens, and they're usually limited to lab settings," said Dr. Carolyn Myers, FendX CEO and inventor. "This invention is part of our ongoing commitment to making surface protection smarter and I believe it shows how mobile devices and AI can work together to bring advanced pathogen detection directly to the user."
About FendX Technologies Inc.
FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing an eco-friendly, smart sponge designed to deliver effective cleaning while minimizing environmental impact. This innovative product complements FendX's broader pipeline, which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and a spray-based coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds an exclusive supply agreement for the eco-sponge and an exclusive license to certain intellectual property related to the use of the sponge, as well as exclusive worldwide licenses and intellectual property for its coating technologies.
ON BEHALF OF THE COMPANY
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, invention and goals related to the development of the invention;; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development of the invention;; risks related to research and development activities for each of the film, spray formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company's products, including the eco-friendly sponge, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP, including the provisional patent application to be assigned to the Company; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263144
FAQ
What is the new patent application filed by FendX Technologies (FDXTF)?
How does FendX's (FDXTF) new pathogen detection technology work?
Who is the inventor of FendX's (FDXTF) new AI pathogen detection platform?
What advantages does FendX's (FDXTF) new pathogen detection system offer?
What markets is FendX (FDXTF) targeting with its new AI pathogen detection platform?
